U.S. Life Sciences Stock News

American Express (AXP) has just approved a 16% uplift in its quarterly dividend, taking the payout to $0.95 per share. For investors, this move puts fresh attention on the stock's income profile. See our latest analysis for American Express. Despite the dividend uplift and a stream of recent announcements around new stadium partnerships, AI investments and a future New York headquarters, the share price has recently come under pressure, with a 30 day share price return of 11.8% and a year to...

Borr Drilling has acquired five premium jack up rigs from Noble Corporation. The company has secured 24 new contract commitments tied to its enlarged fleet. The moves expand NYSE:BORR's operational capacity and increase its contracted work pipeline. For investors watching NYSE:BORR, this fleet deal and new contract haul comes alongside a share price of $5.86 and a 46.9% return year to date. The stock is up 152.6% over the past year and 144.9% over five years, while the three year return...

DENTSPLY SIRONA recently reported fourth-quarter 2025 results showing sales of US$961 million and a net loss of US$146 million, recorded sizeable non-cash impairment charges tied to weaker demand in key technology and implant segments, issued 2026 net sales guidance of US$3.5–3.6 billion, and announced board additions plus an expanded technology distribution partnership with Burkhart Dental Supply. These updates together reveal a company working to realign underperforming businesses, broaden...

Generac Holdings (GNRC) is back in focus after issuing a 2026 outlook that emphasizes large-scale data center generators and growing home automation, along with renewed attention on home standby units following severe winter outages. See our latest analysis for Generac Holdings. That 2026 outlook has arrived after a sharp rebound in sentiment, with a 30-day share price return of 29.21% and a 56.55% year to date share price return. The 1-year total shareholder return of 69.82% contrasts with a...

Nu Holdings (NU) is back in focus after reporting full year 2025 results that showed higher net interest income, net income and earnings per share. This has drawn fresh attention to the stock’s recent pullback. See our latest analysis for Nu Holdings. Despite robust full year 2025 results and upcoming investor visibility at a major technology and telecom conference, Nu Holdings’ recent share price return has softened, with a 7 day share price return of 9.91% and a 30 day share price return of...

Redwire (NYSE:RDW) has introduced its Extensible Low-Profile Solar Array, or ELSA, a new high-performance, low-mass solar array designed for rapid, scalable production for mass-manufactured satellites. The company is also integrating its recent Edge Autonomy acquisition, expanding its presence in autonomous surveillance and reconnaissance technologies used in commercial and defense applications. These moves come as demand grows for power efficient satellite platforms and intelligence systems...

Context for United Bankshares after recent moves United Bankshares (UBSI) has drawn fresh attention after recent share price moves, with the stock closing at $41.38. Investors are weighing this level against the bank's fundamentals and recent return profile. See our latest analysis for United Bankshares. While the latest share price of $41.38 comes after a softer 7 day and 30 day share price return, the 90 day share price return of 8.64% and 1 year total shareholder return of 21.98% suggest...

Axon Enterprise (NasdaqGS:AXON) reported strong Q4 results, with management highlighting what it described as industry leading growth in AI powered public safety tools. The company saw rapid uptake of its generative AI report writing tool, Draft One, among law enforcement customers. Axon expanded further into emergency communications through acquisitions that broaden its public safety technology suite. Recent insider selling by senior executives, including the COO and CFO, has drawn...

Key business snapshot for Viking Holdings Viking Holdings (VIK) has been drawing attention after recent trading, with shares last closing at $75.28. For investors, the immediate reference points are its recent returns and the scale of its current operations. See our latest analysis for Viking Holdings. Recent trading has been choppy, with a 1 day share price return of a 1.49% decline and a 7 day share price return of a 4.93% decline. However, a 90 day share price return of 11.34% and a 1 year...

Quanta Services recently reported fourth‑quarter 2025 results and full‑year figures, with sales of US$7,841.95 million for the quarter and US$28.48 billion for the year, alongside net income of US$315.45 million for the quarter and US$1.03 billion for the year. The company also issued 2026 guidance calling for revenues of about US$33.25–US$33.75 billion and adjusted diluted EPS of US$12.65–US$13.35, underpinned by recent acquisitions and strength in its Electric division. We’ll now examine...

In recent days, Jefferies upgraded Fluence Energy from Hold to Buy, pointing to improved U.S. market conditions and a restated fiscal 2026 revenue and adjusted EBITDA outlook. Fluence’s record project backlog of over US$5.50 billion, supported by almost US$750 million in new quarterly orders, underscores mounting demand from data centers, utilities, and industrial customers. We’ll now examine how Jefferies’ upgrade, centered on Fluence’s record backlog strength, may influence the company’s...

Urban Outfitters (URBN) is back in focus after reporting fourth quarter and full year results, with higher sales in both periods, a mixed picture on net income, and a completed multi year share repurchase program. See our latest analysis for Urban Outfitters. The latest earnings release and completed buyback come after a weaker 30-day share price return of a 7.85% decline and a 90-day share price return of an 11.65% decline. However, the 1-year total shareholder return of 16.67% and 3-year...

Super Group (SGHC) stock is drawing fresh attention after the company reported strong adjusted EBITDA growth and margin expansion in its latest earnings report, along with higher 2026 revenue guidance and a richer dividend program. See our latest analysis for Super Group (SGHC). The latest earnings, higher 2026 revenue guidance and the richer dividend program appear to be supporting renewed momentum, with the 30 day share price return of 23.35% and a 1 year total shareholder return of 66.64%...

In late February 2026, Day One Biopharmaceuticals reported fourth-quarter 2025 revenue of US$53.7 million with a US$21.3 million net loss, and the European regulator’s committee issued a positive opinion supporting conditional marketing authorization of OJEMDA for relapsed or refractory BRAF‑altered pediatric low‑grade glioma. This combination of improving quarterly losses and progress toward conditional European approval for OJEMDA highlights both growing commercial traction and expanding...

AMD and Meta agreed to a multi year partnership for up to 6 gigawatts of AI data center processing, valued at over $100b. The deal includes joint work on new GPU architectures, custom silicon, systems, and software for Meta's future AI platforms. Meta may receive a performance based equity stake in NasdaqGS:AMD as part of the agreement. AMD expanded U.S. manufacturing for advanced AI accelerators and introduced new Ryzen AI 400 Series desktop chips. NasdaqGS:AMD is moving deeper into large...

In recent weeks, Capital One reported very large year-on-year revenue growth that beat analyst expectations, but missed earnings and net interest margin estimates, while facing a new securities-fraud investigation and ongoing integration of Discover and the planned Brex acquisition. These mixed results, combined with regulatory concerns such as potential interest rate caps and insider share sales under a trading plan, highlight how execution, legal risk, and policy shifts could influence...

HCA Healthcare, NYSE:HCA, is preparing for a financial impact linked to expected declines in Affordable Care Act insurance enrollments. The company is adjusting operations to this shift while pursuing AI integration, new emergency care centers, and leadership changes. These moves come as investors weigh the earnings impact projected for 2026 against the company’s longer term strategic initiatives. HCA Healthcare enters this period of change with its shares at $544.41, after a 71.6% return...

In February 2026, Texas Capital Bancshares completed a US$400,000,000 fixed-to-floating rate senior unsecured note offering due 2032, while director Robert W. Stallings bought 40,000 Series B preferred depositary shares and the bank reaffirmed a cash dividend on those shares. Institutional investors such as JPMorgan Chase and Quantbot Technologies expanded their positions as Texas Capital also earned a Best Bank recommendation for middle market clients. We’ll now examine how this combination...

TG Therapeutics and Precision BioSciences reported a new clinical milestone for azercabtagene zapreleucel in progressive multiple sclerosis. The milestone is tied to an exclusive worldwide license for autoimmune diseases between the two companies. The progress with azer cel adds a new autoimmune program alongside TG Therapeutics' existing BRIUMVI franchise. TG Therapeutics, trading on NasdaqCM:TGTX, is drawing fresh attention as it builds out its autoimmune pipeline beyond BRIUMVI. The...

Cigna Group (NYSE:CI) announced a CEO succession, with longtime chief executive David M. Cordani set to retire. Brian Evanko, currently a senior leader within the company, will assume the CEO role. The transition marks a significant leadership change at the top of the health services provider. Cigna Group operates as a global health services company, with a focus on medical benefits, pharmacy benefits, and related services for employers, governments, and individuals. Leadership shifts at a...

Amgen (NasdaqGS:AMGN) and Kyowa Kirin have decided to discontinue clinical development of rocatinlimab. The decision follows emerging safety concerns identified during ongoing clinical trials. All active studies of rocatinlimab are being halted, affecting programs in dermatology and immunology. For you as an investor, this matters because rocatinlimab had been part of Amgen's push into immunology and dermatology, areas that attract significant R&D interest across large biopharma companies...

What investors can see in Exact Sciences today Exact Sciences (EXAS) continues to attract attention as a cancer diagnostics business with US$3,246.99m in annual revenue, a reported net loss of US$207.949m, and a recent share price around US$103.50. See our latest analysis for Exact Sciences. At around US$103.50, Exact Sciences has seen relatively steady short term share price moves, while the 1 year total shareholder return of 117.30% contrasts with a 5 year total shareholder return decline...

Robinhood Markets (NasdaqGS:HOOD) is rolling out new features aimed at higher net-worth customers, including plans for broader wealth management tools beyond stock and crypto trading. The company is hosting a high profile product launch event to showcase services that push its platform toward a more comprehensive financial app. ARK Invest has recently made large purchases of Robinhood shares, adding institutional attention to the stock. Robinhood Markets is trying to reposition itself with...

Colgate-Palmolive stock snapshot and recent performance Colgate-Palmolive (CL) has drawn investor attention recently, with the share price at $95.28 and returns that include a 3.7% gain over the past month and 22.8% over the past 3 months. For a global consumer products group with two main segments (Oral, Personal and Home Care, and Pet Nutrition), these figures give you a reference point for how the stock has behaved before you look more closely at fundamentals. See our latest analysis for...